Wellington Management Group LLP Increases Stock Position in Harrow, Inc. (NASDAQ:HROW)

Wellington Management Group LLP raised its position in Harrow, Inc. (NASDAQ:HROW) by 3.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,179 shares of the company’s stock after acquiring an additional 3,612 shares during the quarter. Wellington Management Group LLP owned approximately 0.29% of Harrow worth $4,639,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of HROW. Mirae Asset Global Investments Co. Ltd. increased its holdings in Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Harrow by 5.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,865 shares of the company’s stock valued at $248,000 after buying an additional 567 shares during the period. Quest Partners LLC bought a new position in shares of Harrow during the third quarter valued at approximately $29,000. nVerses Capital LLC purchased a new stake in Harrow in the second quarter worth $33,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after acquiring an additional 2,048 shares in the last quarter. 72.76% of the stock is owned by institutional investors.

Harrow Trading Up 3.2 %

NASDAQ:HROW opened at $36.64 on Tuesday. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23. The company’s 50-day simple moving average is $46.12 and its 200 day simple moving average is $36.18. The firm has a market capitalization of $1.31 billion, a P/E ratio of -38.98 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Craig Hallum raised their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th. B. Riley cut their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. Finally, Lake Street Capital increased their target price on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.